Haemonetics Corporation's stock surged 8.22% in pre-market trading on Thursday, following the release of its fourth-quarter fiscal 2026 financial results that exceeded analyst expectations.

The medical technology company reported adjusted earnings per share of $1.29 for the quarter, surpassing the FactSet consensus estimate of $1.27. Quarterly net revenue reached $346.4 million, also beating the expected $336.8 million and representing growth from the $330.6 million reported a year earlier.

Additionally, Haemonetics provided a positive outlook for fiscal 2027, guiding for reported revenue growth in the range of 4% to 7%. The company stated that adjusted diluted earnings per share for the fiscal year are expected to be comparable to this revenue growth rate.